The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Maryam Akbari, Omid Reza Tamtaji, Kamran B. Lankarani, Reza Tahrizi, Ehsan Dadgostar, Neda Haghighat, Fariba Kolahdooz, Amir Ghaderi, Mohammad Ali Mansournia and Zatollah Asemi

Abstract

Background: There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and related disorders; however, their findings are controversial. This systematic review and meta-analysis were aimed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders.

Methods: We performed a comprehensive search of the following online databases up to November 2018: Cochrane Library, PubMed, Embase, and Web of Science. The relevant articles were assessed for quality of studies using the Cochrane risk of bias tool.

Results: Out of 2459 citations, 31 articles were appropriate for including to the current meta-analysis. The pooled results indicated that resveratrol use significantly decreased total cholesterol [weighted mean difference (WMD) = −7.65 mg/dL; 95% CI, −12.93, −2.37; \( P < 0.01 \); \( I^2 \): 83.4%] and increased gamma-glutamyl transferase (GGT) concentrations (WMD = 1.76 U/l; 95% CI, 0.58, 2.94; \( P < 0.01 \); \( I^2 \): 20.1%). We found no significant effect of resveratrol supplementation on triglycerides (WMD = −5.84 mg/dL; 95% CI, −12.68, 1.00; \( P = 0.09 \); \( I^2 \): 66.8%), LDL- (WMD = −2.90 mg/dL; 95% CI, −10.88, 5.09; \( P = 0.47 \); \( I^2 \): 96.0%), HDL-cholesterol (WMD = 0.49 mg/dL; 95% CI, −0.80, 1.78; \( P = 0.45 \); \( I^2 \): 74.0%), alanine aminotransferase (ALT) (WMD = −0.14 U/l; 95% CI, −3.69, 3.41; \( P = 0.93 \); \( I^2 \): 79.6%), and aspartate aminotransferase (AST) (WMD = −0.34 U/l; 95% CI, −2.94, 2.27; \( P = 0.80 \); \( I^2 \): 88.0%) concentrations.

Conclusions: This meta-analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders.

Keywords: Resveratrol, Lipid profiles, Liver enzymes, Metabolic syndrome, Meta-analysis
Background

Increased concentrations of circulating lipid profiles are a strong risk factor for cardiovascular disease [1]; high concentrations of total-, LDL-cholesterol, or triglycerides, as well as, low concentrations of HDL-cholesterol are consistently correlated with incidence of cardiovascular diseases (CVDs) [2, 3]. Metabolic syndrome (MetS) is considered as an insulin resistant syndrome comprising impaired glucose tolerance, decreased insulin sensitivity, dyslipidemia, central obesity, and hypertension, all of which are well-established risk factors for CVDs [4]. In addition, MetS is correlated with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), colorectal disease, atrial fibrillation and hypothyroidism [5, 6]. NAFLD is also associated with impaired liver enzymes, including, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), dysfunctional fat cells, and adipose tissue insulin resistance, resulting in hyperglycemia and dyslipidemia [7, 8].

The beneficial effects of resveratrol, plant sterols, and stanols on lipid profiles and modifying cardiovascular risk factors have been reported [9–13]. Resveratrol is a natural polyphenolic compound found mainly in peanuts and in the skin of red grapes that is used as a dietary supplement to improve metabolic profiles [14]. The effects of resveratrol supplementation on lipid profiles and liver enzymes have already been evaluated; however, these findings are controversial. In a meta-analysis on seven randomized controlled trials (RCTs), conducted by Sahebkar et al. [15], resveratrol supplementation had no effect on lipid profile. In another meta-analysis conducted by Hausenblas et al. [16], resveratrol supplementation to patients with T2DM was more effective on the systolic blood pressure, hemoglobin A1c, and creatinine, but did not affect fasting glucose, insulin resistance, diastolic blood pressure, insulin, triglycerides, LDL- and HDL-cholesterol concentrations. However, another meta-analysis of RCTs showed no effects of resveratrol supplementation on total-, LDL-cholesterol, triglycerides, and fasting glucose concentrations [17]. Differences in study design, study population’s characteristics, the dosage of resveratrol used, and the duration of intervention might explain the discrepancies among different studies.

We aimed to systematically review the trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes to summarize the impact among patients with MetS and related disorders.

Methods

PRISMA guideline (ERF) (the preferred reporting items for systematic reviews and meta-analyses) was used to design and implement this meta-analysis.

Search strategy

Two independent authors (MA and OT) performed a comprehensive search to identify the relevant RCTs through inception up to November 2018. Online databases, including Cochrane Library, PubMed, Embase, and Web of Science databases by using the following MeSH and text keywords: patients [“Mets” OR “NAFLD” OR “disorders related to MetS” OR “diabetes” OR “T1DM” OR “T2DM” OR “overweight” OR “obese” OR “chronic kidney disease” OR “hypertension” OR “high blood pressure” OR “dyslipidemia” OR “CVD”], intervention (“resveratrols” OR “resveratrol” AND “use” OR “supplementation” OR “intake”), and outcomes lipid profiles [“triglycerides” OR “total cholesterol” OR “LDL-cholesterol” (LDL-C) OR “HDL-cholesterol” (HDL-C) AND liver measurements [“alanine aminotransferase (ALT)” OR “aspartate aminotransferase (AST)” OR “gamma-glutamyl transferase (GGT)”]. Clinical trials retrieved that estimated the effect of resveratrol intake on lipid profiles and/or liver enzymes. Our search strategy was limited to human RCTs published in English language. We conducted a manual search in the reference list's included articles and pervious relevant reviews to find other additional articles.

Selection criteria

The following inclusion criteria were used to select the related articles: RCTs were among humans (with parallel or cross-over design) with metabolic diseases, administered resveratrol supplements in the intervention group and received placebo in the comparison group, contained sufficient data on mean changes of lipid profiles (including, triglycerides, total-, LDL-, and HDL-cholesterol concentrations), and liver enzymes (ALT, AST, and GGT concentrations), along with standard deviation (SD) or related 95% confidence intervals (CIs) at the baseline and at the end of trial for the intervention and placebo groups. RCTs which were not placebo controlled or other type of studies including animal, in vitro, case report, and case series, also abstracts or protocols without full texts, and studies with dosage of resveratrol lower than 20 mg/day were excluded.

Data extraction

Two independent investigators (MA and OT) extracted data using a standard Excel forms according to the following items: first author’s name, publication year, country, demographic characteristics of participants, study methods, sample size (intervention/placebo groups), dose of treatment, type of intervention, type of diseases, the mean ± (SD) of changes for triglycerides, total-, LDL-, HDL-cholesterol, ALT, AST, and GGT concentrations in the intervention and placebo groups at the baseline and at the end of intervention. If the
outcomes were reported by different doses, types of supplements, or duration of the intervention, we treated each situation as a separate study. Disagreements were resolved by discussion with a third author (ZA).

**Quality assessment**
The Cochrane Collaboration risk of bias tool was applied to assess the quality of selected RCTs using the following domains: “randomization generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome data and selective outcome reporting, and the other sources of bias”.

**Statistical analysis**
All statistical analyses were conducted using STATA software version 12.0 (Stata Corp., College Station, TX) and RevMan V.5.3 software (Cochrane Collaboration, Oxford, UK). Weighted mean differences (WMDs) and 95% CIs were considered as the overall combined effect sizes. Heterogeneity across included trials was examined using the Cochrane’s Q and $I^2$ statistics. $I^2 > 50\%$ with $P < 0.05$ indicated that a significant heterogeneity exists, therefore, the DerSimonian and Laird random effects model were used to combine effect sizes; otherwise, the inverse variance fixed-effect model was applied. Sensitivity analyses were performed to evaluate the impact of each included clinical trials on the validity of the overall combined WMDs. Subgroup analyses were conducted to examine the source of heterogeneity according to the following possible moderator variables; type of interventions (resveratrol plus other nutrients or drugs vs. resveratrol alone), dosage of resveratrol (> 250 vs. $\leq 250$ mg/day), duration of intervention ($\leq 8$ vs. $> 8$ weeks), and type of chronic condition (e.g. overweight, or obese, or other chronic diseases vs. T2DM). The potential evidence of publication bias was determined using

---

**Fig. 1** Literature search and review flowchart for selection of studies

[Diagram of the literature search and review flowchart]
| Authors (Ref) | Publication year | Sample size (control/ intervention) | Population/Country | Intervention (name and daily dose) | Duration | Presented data | Age (y) (control, intervention) |
|--------------|------------------|-------------------------------------|--------------------|-------------------------------------|----------|----------------|-------------------------------|
| Arzola-Paniagua et al. [18] | 2016 | 24/15 | Obesity/Mexico | Resveratrol 300 mg | 24 weeks | TG | 33.7 ± 11.9 | 38.8 ± 9.59 |
| Arzola-Paniagua et al. [18] | 2016 | 21/24 | Obesity/Mexico | Resveratrol 300 mg | 24 weeks | TG | 40.96 ± 10.0 | 39.76 ± 8.91 |
| Bashmakov YK et al. [19] | 2014 | 10/14 | T2DM/Egypt | Resveratrol 100 mg | 2 months | HDL-C, LDL-C, and TC | 54 ± 101, 59 ± 6.6 |
| Bhatt JK et al. [20] | 2014 | 5/5 | T2DM/Singapore | Resveratrol 3000 mg | 12 weeks | TG, HDL-C, LDL-C, and ALT | 55 ± 7, 56 ± 5.3 |
| Imamura H et al. [22] | 2017 | 25/25 | T2DM/Japan | Resveratrol 100 mg | 12 weeks | TG, HDL-C, TC | 57 ± 10.6, 58 ± 10.1 |
| Zare Javid A et al. [23] | 2017 | 22/21 | T2DM/Iran | Resveratrol 480 mg | 4 weeks | TG | 49.1 ± 7.4, 509 ± 8.9 |
| Kjær TN et al. [24] | 2017 | 12/21 | MetS/Denmark | Resveratrol 150 mg | 16 weeks | TG, HDL-C, LDL-C, TC, and ALT | 40.1 ± 6.6, 47.8 ± 6.36 |
| Kjær TN et al. [24] | 2017 | 12/21 | MetS/Denmark | Resveratrol 1000 mg | 16 weeks | TG, HDL-C, LDL-C, TC, and ALT | 51.9 ± 5.86, 47.8 ± 6.36 |
| Kumar BJ et al. [25] | 2013 | 29/28 | T2DM/India | Resveratrol 480 mg | 6 months | TG, HDL-C, LDL-C, and TC | 56.7 ± 8.91, 57 ± 9.7 |
| Militaru C et al. [26] | 2013 | 29/29 | Stable angina/Romania | Resveratrol 20 mg | 2 months | TG, HDL-C, LDL-C, and TC | 64.9 ± 5.8, 64.2 ± 7.1 |
| Militaru C et al. [26] | 2013 | 29/29 | Stable angina/Romania | Resveratrol 20 mg | 2 months | TG, HDL-C, LDL-C, and TC | 66.3 ± 5.5, 63.7 ± 6.2 |
| Most J et al. [27] | 2016 | 20/18 | Obese/Netherlands | Resveratrol 80 mg + 282 mg epigallocatechin-3-gallate | 12 weeks | TG, HDL-C, LDL-C, and TC | 36 ± 1.3, 38 ± 9.83 |
| Movahed A et al. [28] | 2013 | 31/33 | T2DM/Iran | Resveratrol 1000 mg | 45 days | TG, HDL-C, LDL-C, TC, ALT, AST, and GGT | 52.45 ± 6.18, 51.81 ± 6.99 |
| Poulsen MM et al. [29] | 2013 | 12/12 | Obese/ Denmark | Resveratrol 1500 mg | 4 weeks | TG, HDL-C, LDL-C, TC, and ALT | 44.7 ± 12.1, 319 ± 10.03 |
| Seyedehrahimi S et al. [30] | 2018 | 23/23 | T2DM/ Iran | Resveratrol 800 mg | 2 months | TG, HDL-C, LDL-C, TC, ALT, and AST | 54.96 ± 6.37, 58.67 ± 6.06 |
| Méndez-del Villar M et al. [31] | 2014 | 10/11 | MetS/Mexico | Resveratrol 1000 mg | 3 months | TG, HDL-C, LDL-C, and TC | 39.8 ± 5.4, 40.3 ± 5.4 |
| Witte AV et al. [32] | 2014 | 23/23 | Overweight subjects/Germany | Resveratrol 200 mg | 26 weeks | TG and TC | 64.8 ± 6.8, 63.7 ± 5.3 |
| Ochady JS et al. [33] | 2014 | 10/10 | NAFLD/ Australia | Resveratrol 3000 mg | 8 weeks | TG, HDL-C, LDL-C, TC, ALT, AST, and GGT | 48.8 ± 12.2, 47.5 ± 11.2 |
| Chen S et al. [34] | 2015 | 30/30 | NAFLD/ China | Resveratrol 300 mg | 12 weeks | TG, HDL-C, LDL-C, TC, ALT, AST, and GGT | 45 ± 10.0, 43.5 ± 11.0 |
| Faghihzadeh F et al. [35] | 2015 | 25/25 | NAFLD/Iran | Resveratrol 500 mg | 12 weeks | TG, HDL-C, LDL-C, TC, ALT, AST, and GGT | 44.04 ± 10.10, 46.28 ± 9.52 |
| Kantartzis K et al. [36] | 2018 | 52/53 | Overweight and insulin resistant Subjects/Germany | Resveratrol 150 mg | 12 weeks | TG, HDL-C, LDL-C, TC, ALT, AST, and GGT | 18–70 |
| Most J et al. [37] | 2018 | 14/11 | Obesity/Netherlands | Resveratrol 80 mg + 282 mg epigallocatechin-3-gallate | 12 weeks | TG | 36 ± 3, 40 ± 3 |
| Khodabandehloo H et al. [38] | 2018 | 20/25 | T2DM/ Iran | Resveratrol 800 mg/day | 8 weeks | TG, HDL-C, LDL-C, TC, ALT, and AST | 56.48 ± 6.72, 61.10 ± 5.61 |
| Chekalina NL et al. [39] | 2016 | 33/30 | CAD/Ukraine | Resveratrol 100 mg | 2 months | TG, HDL-C, LDL-C, and TC | 48–72 |
| Fujitaka K et al. [40] | 2011 | 17/17 | MetS/Japan | Trans resveratrol 100 mg | 3 months | TG, HDL-C, and LDL-C | 63 ± 9 |
| Authors (Ref) | Publication year | Sample size (control/intervention) | Population/Country | Intervention (name and daily dose) | Duration | Presented data | Age (y) (control, intervention) |
|--------------|------------------|----------------------------------|-------------------|-----------------------------------|----------|----------------|-------------------------------|
| Cicero AF et al. [41] | 2016            | Overall 25                        | Hypercholesterolemic/Italy | Resveratrol 20 mg and monacolins from *M. purpureus* 10 mg | 4 weeks | TG, HDL-C, LDL-C, TC, ALT, and AST | 62 ± 14                      |
| Biesinger S et al. [42] | 2016            | Overall 18                        | Hypertension/USA | Resveratrol 60 mg | 4 weeks | TG, HDL-C, LDL-C, and TC | 44 ± 3                       |
| Timmers S et al. [43] | 2011            | Overall 11                        | Obesity/Netherlands | Resveratrol 150 mg | 30 days | TG | 52.5 ± 6.95, 52.5 ± 6.95 |
| van der Made SM et al. [44] | 2015           | Overall 45                        | Obesity/Netherlands | Resveratrol 150 mg | 4 weeks | HDL-C and TC | 61 ± 7                       |
| de light M et al. [45] | 2018            | Overall 13                        | T2DM/Netherlands | Resveratrol 150 mg | 30 days | HDL-C, LDL-C, TC, AST, and GGT | 66 ± 7                       |
| Simental-Mendía LE et al. [46] | 2019      | 31/31                             | Dyslipidaemia/México | Resveratrol 100 mg | 8 weeks | TG, HDL-C, LDL-C, and TC | 20–65                       |
| Fodor K et al. [47] | 2018            | 46/81                             | Stroke/Romania | Resveratrol 100 mg + Allopathic treatment + physical rehabilitation | 48 weeks | TG, HDL-C, LDL-C, and TC | 65.03 ± 8.24, 64.78 ± 6.32 |
| Fodor K et al. [47] | 2018            | 46/55                             | Stroke/Romania | Resveratrol 200 mg + Allopathic treatment + physical rehabilitation | 48 weeks | TG, HDL-C, LDL-C, and TC | 64.52 ± 8.05, 64.78 ± 6.32 |
| Mazza A et al. [48] | 2018            | 30/30                             | Hypertensive and hypercholesterolemic subjects/Italy | Nutraceutical compounds capsule containing resveratrol 20 mg + standardized Mediterranean diet | 4 weeks | TG, HDL-C, LDL-C, TC, ALT, and AST | 51.5 ± 7.8, 530 ± 8.1 |

**CAD**: Coronary artery disease, **MetS**: Metabolic syndrome, **NAFLD**: Non-alcoholic fatty liver disease, **NR**: Not reported, **T2DM**: Type 2 diabetes mellitus, **LDL-C**: Low-density lipoprotein-cholesterol, **HDL-C**: High-density lipoprotein-cholesterol, **ALT**: Alanine aminotransferase, **AST**: Aspartate aminotransferase, **GGT**: Gamma-glutamyl transferase
Egger’s- and Begg’s-test. P-value less than 0.05 were considered as statistically significant.

**Results**

In initial online database searches, 2459 reports were identified. After removing duplicates citations by reviewing titles and abstracts and excluding the irrelevant citations, 31 studies (35 effect sizes) were finally included. Figure 1 shows the stepwise with more details of the identification and selection of the relevant articles. All 35 included effect sizes were randomized, placebo-controlled trial. Twenty-nine studies were conducted using parallel design and six studies had cross-over design. The total number of the participants among included studies was 1722 individuals (890 persons in the resveratrol group; and 832 in the placebo group). Thirty-two studies calculated the influences of resveratrol intake on triglycerides, twenty-eighth on total cholesterol, twenty-seven on LDL-cholesterol, twenty-nine on HDL-cholesterol, thirteen on ALT, ten on AST, and five studies on GGT concentrations. The duration of resveratrol supplements ranged from four to 48 weeks and dosage of the intervention varied from 20 to 3000 mg/day among included articles. Table 1 illustrates the characteristics of the included articles. The quality assessment of included articles performed by authors’ judgment according to each bias item is presented in Fig. 2.

**Main outcomes**

**Effects of resveratrol supplementation on lipid profiles and liver enzymes**

The impact of resveratrol supplementation on lipid profiles and liver enzymes are indicated in Fig. 3. The combined findings, using random-effects model showed that resveratrol intake significantly decreased total cholesterol (\(=-7.65 \text{ mg/dL}; 95\% \text{ CI, } -12.93, -2.37; P < 0.01; I^2: 83.4\%\)) and increased GGT concentrations (WMD = 1.76 U/l; 95% CI, 0.58, 2.94; \(P < 0.01; I^2: 20.1\%\)). We found no significant effect of resveratrol intake on triglycerides (WMD = -5.84 mg/dL; 95% CI, -12.68, 1.00; \(P = 0.09; I^2: 66.8\%\)), LDL- (WMD = -2.90 mg/dL; 95% CI, -10.88, 5.09; \(P = 0.47; I^2: 96.0\%\)), HDL-cholesterol (WMD = 0.49 mg/dL; 95% CI, -0.80, 1.78; \(P = 0.45; I^2: 74.0\%\)), ALT (WMD = -0.14 U/l; 95% CI, -3.69, 3.41; \(P = 0.93; I^2: 79.6\%\)), and AST (WMD = -0.34 U/l; 95% CI, -2.94, 2.27; \(P = 0.80; I^2: 88.0\%\)) concentrations.

**Subgroup analyses**

The findings of subgroup analyses indicated that there were no significant changes between before and after subgroup analyses combined WMDs for lipid profiles and liver enzymes. The results of subgroup analyses are indicated in Table 2.

**Sensitivity analyses**

Sensitivity analyses showed no significant changes between the pre- and post-sensitivity combined WMDs for triglycerides, HDL-cholesterol, ALT, AST, and GGT concentrations. We found that there was a significant effect between before and after sensitivity pooled WMD for total cholesterol after removing Bhatt et al. [20] study (WMD -5.76; 95% CI, -12.23, 0.70), and for LDL-cholesterol after removing Faghihzadeh et al. [35] study (WMD -6.32; 95% CI, -11.41, -1.22) (Table 3).

**Publication bias and quality assessment**

Egger and Begg’s tests indicated no significant effect of possible publication bias for meta-analyses calculating the influence of resveratrol intake on triglycerides (P Begg’s test = 0.74, P Egger’s test = 0.69), LDL-cholesterol (P_Bg = 0.07, P_Ee = 0.53), HDL-cholesterol (P_Bg = 0.88, P_Ee = 0.98), ALT (P_Bg = 0.39, P_Ee = 0.11), AST (P_Bg = 0.42, P_Ee = 0.90), and GGT concentrations (P_Bg = 0.14, P_Ee = 0.60). The authors found that there was a significant effect of the potential of publication bias for total-cholesterol (P_Bg = 0.17, P_Ee = 0.00). We applied non-
Fig. 3 A-G Meta-analysis standardized mean differences estimates for (a) triglycerides (b) for total-, (c) for LDL-, (d) for HDL-cholesterol, (e) for ALT, (f) for AST, and (g) for GGT concentrations in the resveratrol and control groups (CI = 95%)
| Variables         | Number of WMD included | Subgroups                             | Pooled WMD (random effect) | 95% CI | I² (%) | Overall I² (%) |
|-------------------|------------------------|---------------------------------------|-----------------------------|--------|--------|---------------|
| Triglycerides     | 32                     | Overall                               | -5.84                       | -12.68, 1.00 | 66.8   | 66.8          |
|                   |                        | Type of intervention                  | -8.81                       | -13.67, -3.96 | 0.0    |                |
|                   |                        | Resveratrol                           | -5.06                       | -14.41, 4.29 | 71.8   |                |
|                   |                        | Dosage of resveratrol (mg/day)        | 1.43                        | -7.84, 10.69 | 0.0    |                |
|                   |                        | ≥ 500 mg resveratrol                  | -8.07                       | -16.20, 0.05 | 74.1   |                |
|                   |                        | < 500 mg resveratrol                  | -4.93                       | -19.17, 9.31 | 70.8   |                |
|                   |                        | Duration of study (week)              | -5.40                       | -11.53, 0.74 | 40.5   |                |
|                   |                        | Type of disease                       | 1.44                        | -13.46, 16.34 | 0.0    |                |
|                   |                        | Overweight or obese                   | 1.44                        | -13.46, 16.34 | 0.0    |                |
|                   |                        | Other                                 | -5.41                       | -15.72, 4.91 | 74.1   |                |
|                   |                        | T2DM                                  | -8.06                       | -21.30, 5.17 | 58.4   |                |
|                   |                        | Type of disease                       | 1.93                        | -5.65, 9.50 | 0.0    |                |
|                   |                        | Overweight or obese                   | 1.93                        | -5.65, 9.50 | 0.0    |                |
|                   |                        | Other                                 | -8.32                       | -16.28, -0.36 | 83.8   |                |
|                   |                        | T2DM                                  | -8.32                       | -16.28, -0.36 | 83.8   |                |
|                   |                        | Type of disease                       | 3.47                        | -6.35, 13.29 | 0.0    |                |
|                   |                        | Overweight or obese                   | 3.47                        | -6.35, 13.29 | 0.0    |                |
|                   |                        | Other                                 | -2.94                       | -14.71, 8.82 | 97.0   |                |
|                   |                        | T2DM                                  | -2.94                       | -14.71, 8.82 | 97.0   |                |
|                   |                        | ≥ 12 weeks                            | 0.59                        | -12.65, 13.84 | 97.6   |                |
|                   |                        | Overweight or obese                   | 3.47                        | -6.35, 13.29 | 0.0    |                |
|                   |                        | Other                                 | -2.94                       | -14.71, 8.82 | 97.0   |                |
|                   |                        | T2DM                                  | -2.94                       | -14.71, 8.82 | 97.0   |                |
|                   |                        | ≥ 12 weeks                            | 0.59                        | -12.65, 13.84 | 97.6   |                |
|                   |                        | Type of disease                       | 4.63                        | -0.80, 1.78 | 74.0   | 74.0          |
|                   |                        | Overweight or obese                   | 4.63                        | -0.80, 1.78 | 74.0   | 74.0          |
|                   |                        | Other                                 | -0.02                       | -1.52, 1.49 | 73.4   |                |
|                   |                        | T2DM                                  | -0.02                       | -1.52, 1.49 | 73.4   |                |
|                   |                        | ≥ 500 mg resveratrol                  | 0.55                        | -2.21, 3.32 | 78.2   |                |
|                   |                        | < 500 mg resveratrol                  | 0.31                        | -1.11, 1.72 | 69.1   |                |
|                   |                        | < 12 weeks                            | 0.26                        | -1.66, 2.18 | 72.1   |                |
|                   |                        | ≥ 12 weeks                            | 0.79                        | -0.92, 2.50 | 71.1   |                |
|                   |                        | Type of disease                       | 0.61                        | -1.55, 2.76 | 69.3   |                |
|                   |                        | Overweight or obese                   | 0.61                        | -1.55, 2.76 | 69.3   |                |
|                   |                        | Other                                 | 0.61                        | -1.55, 2.76 | 69.3   |                |
|                   |                        | ≥ 12 weeks                            | 0.79                        | -0.92, 2.50 | 71.1   |                |
|                   |                        | Type of disease                       | 0.63                        | -1.43, 2.70 | 74.3   |                |
|                   |                        | Overweight or obese                   | 0.63                        | -1.43, 2.70 | 74.3   |                |
|                   |                        | Other                                 | 0.63                        | -1.43, 2.70 | 74.3   |                |
|                   |                        | ≥ 12 weeks                            | 0.79                        | -0.92, 2.50 | 71.1   |                |
|                   |                        | Type of disease                       | 0.63                        | -1.43, 2.70 | 74.3   |                |
|                   |                        | Overweight or obese                   | 0.63                        | -1.43, 2.70 | 74.3   |                |
|                   |                        | Other                                 | 0.63                        | -1.43, 2.70 | 74.3   |                |
|                   |                        | ≥ 12 weeks                            | 0.79                        | -0.92, 2.50 | 71.1   |                |
parametric method (Duval and Tweedie) to calculate the findings of censored articles for total-cholesterol; however, pooled WMDs findings did not statistically significantly change after using Duval and Tweedie test.

**Discussion**

The findings of current systematic review and meta-analysis showed that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations.

MetS and related disorders are characterized by changes in fatty acid metabolism, which finally results in decreased HDL-cholesterol, and increased LDL-cholesterol as well as, triglycerides concentrations. As dyslipidemia is a well-established risk factor for MetS, diabetes, and CVDs, circulating lipid profiles are routinely addressed by pharmacotherapy. We found that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations.

### Table 2 The association between resveratrol intake on lipid profiles and liver enzymes using subgroup analysis (Continued)

| Variables | Number of WMD included | Subgroups | Pooled WMD | 95% CI | I² (%) | Overall I² (%) |
|-----------|------------------------|-----------|------------|--------|--------|---------------|
| ALT       |                        | Overall   | −0.14      | −3.69, 3.41 | 79.6   | 79.6          |
|           |                        | Type of intervention | Resveratrol plus other nutrients or drugs | 2.00 | −1.56, 5.56 | 25.2 |
|           |                        | Resveratrol | −0.74 | −4.88, 3.41 | 78.9 |
|           |                        | Dosage of resveratrol (mg/day) | ≥ 500 mg resveratrol | −1.77 | −6.37, 2.84 | 80.8 |
|           |                        |           | < 500 mg resveratrol | 2.19 | −0.51, 4.89 | 0.0 |
|           |                        | Duration of study (week) | < 12 weeks | 1.52 | −0.39, 3.43 | 0.0 |
|           |                        |           | ≥ 12 weeks | −2.01 | −8.09, 4.08 | 78.2 |
|           |                        | Type of disease | Overweight or obese | 1.34 | −5.36, 8.04 | 0.0 |
|           |                        | Other     | −1.76 | −7.00, 3.48 | 83.8 |
|           |                        | T2DM      | 1.75 | −1.43, 4.92 | 27.3 |
| AST       |                        | Overall   | −0.34      | −2.94, 2.27 | 88.0   | 88.0          |
|           |                        | Type of intervention | Resveratrol plus other nutrients or drugs | −2.22 | −11.24, 6.79 | 93.7 |
|           |                        | Resveratrol | 0.18 | −2.70, 3.05 | 87.5 |
|           |                        | Dosage of resveratrol (mg/day) | ≥ 500 mg resveratrol | 0.28 | −3.78, 4.35 | 84.1 |
|           |                        |           | < 500 mg resveratrol | −0.83 | −4.42, 2.76 | 87.5 |
|           |                        | Duration of study (week) | < 12 weeks | 0.96 | −1.92, 3.84 | 79.1 |
|           |                        |           | ≥ 12 weeks | −3.16 | −6.43, 0.12 | 76.1 |
|           |                        | Type of disease | Overweight or obese | −0.12 | −3.54, 3.30 | – |
|           |                        | Other     | −2.61 | −6.29, 1.06 | 83.6 |
|           |                        | T2DM      | 1.23 | 0.30, 2.17 | 0.0 |
| GGT       |                        | Overall   | 1.76      | 0.58, 2.94 | 20.1   | 20.1          |
|           |                        | Type of intervention | Resveratrol plus other nutrients or drugs | – | – | – |
|           |                        | Resveratrol | 1.76 | 0.58, 2.94 | 20.1 |
|           |                        | Dosage of resveratrol (mg/day) | ≥ 500 mg resveratrol | 1.05 | −1.31, 3.40 | 55.9 |
|           |                        |           | < 500 mg resveratrol | 2.00 | 0.63, 3.36 | 0.0 |
|           |                        | Duration of study (week) | < 12 weeks | 2.01 | 0.71, 3.32 | 0.0 |
|           |                        |           | ≥ 12 weeks | 0.60 | −2.17, 3.37 | 52.2 |
|           |                        | Type of disease | Overweight or obese | 1.74 | −8.78, 12.26 | – |
|           |                        | Other     | 0.52 | −2.35, 3.39 | 75.8 |
|           |                        | T2DM      | 2.00 | 0.71, 3.32 | 0.0 |

ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase
The current meta-analysis demonstrated that taking resveratrol supplements by patients with MetS and related disorders was associated with a significant reduction in GGT, but did not affect ALT and AST concentrations. In a study by Asghari et al. [58], resveratrol supplementation at a dosage of 600 mg/day for 12 weeks to patients with NAFLD did not modify liver enzymes and oxidative/anti-oxidative status. In addition, previous animal studies have claimed that resveratrol protects the liver against steatosis [59] and decreases intracellular lipids in the liver [60]. In another study, Heebøll et al. [61] demonstrated no significant improvement in the intrahepatic lipid content and the circulating concentrations of liver enzymes following resveratrol supplementation at a dosage of 1500 mg/day for 6 months among patients with NAFLD. An 8-week resveratrol supplementation at a dosage of 3000 mg/day, not only failed to show any significant improvements in NAFLD features, but also significantly increased liver enzymes concentrations [33]. Also, Faghihzadeh et al. [62] demonstrated that 500 mg/day resveratrol supplementation for 3 months among people with NAFLD significantly improved liver steatosis and ALT concentrations. A similar study with 600 mg/day resveratrol also documented a significant improvement in liver enzymes concentrations without any changes in liver steatosis degree [34]. These inconsistent findings could be related to the stage of disease, type of diseases, the method of measuring liver fat content, different dosage of resveratrol used, or baseline metabolic characteristics of the participants.
Conclusions
This meta-analysis demonstrated that resveratrol supplementation to the patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. Therefore, resveratrol supplementation to patients with MetS and related disorders may have a potential cardioprotective effect through the reduction of total cholesterol and GGT concentrations.

Abbreviations
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CADs: Coronary artery diseases; GGT: Gamma-glutamyl transferase; HDL-C: High-density lipoprotein-cholesterol; LDL-C: Low-density lipoprotein-cholesterol; MetS: Metabolic syndrome; NAFLD: Non-alcoholic fatty liver disease; NR: Not reported; T2DM: Type 2 diabetes mellitus

Acknowledgements
The present study was supported by a grant from the Vice-chancellor for Research, SUMS, Shiraz, and Iran.

Authors’ contributions
ZA contributed in conception, design, statistical analysis and drafting of the manuscript. MA, O-RT, K-BL, RT, ED, NH, FK, AG and M-AM contributed in data collection and manuscript drafting. All authors approved the final version for submission. ZA oversaw the study.

Funding
The present study was founded by a grant from the Vice Chancellor for Research, Shiraz University of Medical Sciences, in Iran.

Availability of data and materials
The primary data for this study is available from the authors on direct request.

Ethics approval and consent to participate
This study was considered exempt by the SUMS Institutional Review Board.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. 2Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, IR, Iran. 3Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 4Halal Research Center of IRI, FDA, Tehran, Iran. 5Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. 6Indigenous and Global Health Research, Department of Medicine, University of Alberta, Edmonton, Canada. 7Department of Addiction studies, School of Medical, Kashan University of Medical Sciences, Kashan, Iran. 8Clinical Research Development Unit-Matini/Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, IR, Iran. 9Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Received: 1 April 2019 Accepted: 24 January 2020
Published online: 17 February 2020

References
1. Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40:195–211.
2. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec cardiovascular study. Arch Intern Med. 2001;161:2685–92.
3. Larmarche B, Tchernof A, Mojonari S, Cantin B, Dagenaes GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Circulation. 1997;95:69–75.
4. Lee SW, Lee TY, Yang SS, Tung CF, Yeh HZ, Chang CS. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: either non-obese or obese Chinese population. Hepatobiliary Pancreatic Dis Int. 2018;17:45–8.
5. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60:829–36.
6. Pagadala MR, Zein CO, Dasarathy S, Yerian LM, Lopez R, McCullough AJ. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57:528–34.
7. Puri P, Baillie RA, West MM, Minihai F, Choudhury J, Cheung O, et al. A lipodipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081–90.
8. Dongiovanni F, Stender S, Pietrelli A, Mancia RM, Cespiati A, Petta S, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283:356–70.
9. Sahebkar A, Serban MC, Glbza-Brozok A, Mikhailidis DP, Ciocero AF, Ryz J, et al. Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition. 2016;32:1179–92.
10. Patti AM, Al-Rasadi K, Giglio RV, Nikolic D, Mamima C, Castellino G, et al. Natural approaches in metabolic syndrome management. Arch Med Sci. 2014;10:422–41.
11. Ciocero AFG, Colletti A, Bajakart G, Descamps O, Djuric DM, Ezhov M, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel. Arch Med Sci. 2017;13:965–1005.
12. Sosnowska B, Penson P, Banach M. The role of nutraceuticals in the prevention of cardiovascular disease. Cardiovasc Diagn Ther. 2017;7:521–331.
13. Banach M, Patti AM, Giglio RV, Ciocero AFG, Atanasev AG, Bajakart G, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72:956–118.
14. Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidemia. Nat Rev Endocrinol. 2017;13:278–88.
15. Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2013;71:822–35.
16. Hosenblau HA, Schoulda IA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus–systematic review and meta-analysis. Mol Nutr Food Res. 2015;59:147–59.
17. Sahebkar A, Serban C, Ursouion S, Wong ND, Muntner P, Graham IM, et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors–results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2015;189:17–55.
18. Arzola-Paniagua MA, Garcia-Salgado Lopez ER, Calvo-Vargas CG, Guavara-Cruz M. Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial. Obesity (Silver Spring, Md). 2016;24:1454–63.
19. Bashmakov YK, Assaad-Khalli SH, Abou Seif M, Udumyan R, Megallaa M, Rohoma KH, et al. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. EBioMedicine. 2014;8:61307.
20. Bhat JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32:537–41.
21. Goh KP, Lee HY, Lau DP, Supaat W, Chan YH, Koh AF. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exerc Metab. 2014;4:22–13.
22. Imamura H, Yamagushi T, Nagayama M, Saiki A, Shitata A, Tatsuno I. Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus. Int J Cardiol. 2017;284:577–583.
23. Zare Javid A, Hormoznejad R, Yousefimanesh HA, Zakerkhish M, Haghighi-Zadeh MH, Dehghan P, et al. The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Phytother Res. 2017;31:108–14.
24. Kjaer TN, Ornstrup MJ, Poulsen MM, Stodkilde-Jorgensen H, Jensen N, Jorgensen JOL, et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab. 2017;102:1642–51.
25. Kumar BJ, Joghee NM. Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. Int Res J Pharm. 2013;4:426–9.
26. Militaru C, Doniou C, Craciun A, Scorei ID, Bulea CA, Scorei RI. Oral resveratrol and calcium fructose supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition. 2013;29:178–83.

27. Most J, Timmers S, Warnke I, Jocken JW, van Boekhoven M, de Groot P, et al. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. Am J Clin Nutr. 2016;104:215–27.

28. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantar-Hormozi M, et al. Anti-hyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013;2013:851267.

29. Poulsen MM, Vestergaard PF, Classen BF, Radko Y, Christensen LP, Stodkilde-Jørgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186–95.

30. Seyyedehshahri H, Khodabandehlohi H, Nasli Esfahani E, Mershani R. The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Acta Diabetol. 2018;55:341–53.

31. Mendez-del Villar M, Gonzalez-Ottu M, Martinez-Abundis E, Perez-Rubio KG, Lizana-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and body composition. Diabetes. 2013;62:1186–95.

32. Witte AV, Kerti L, Margulies DS, Fiol A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci. 2014;34:7862–70.

33. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092–103 e1–6.

34. Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Digest Liver Dis. 2015;47:226–32.

35. Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796–803.

36. Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H, et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab. 2018;20:1793–7.

37. Most J, Warnke I, Boekhoven JW, Jocken JW, de Groot P, Friedel A, et al. The effects of polyphenol supplementation on adipose tissue morphology and function in metabolic syndrome receiving standard treatment. Nutr Res. 2011;31:842–56.

38. Most J, Warnke I, Boekhoven JW, de Groot P, Friedel A, et al. The effects of resveratrol on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Food Funct. 2018;9:3845–52.

39. Tabrizi R, Tamtaji OR, Lankarani KB, Akbari M, Dadgostar E, Dabbaghmanesh MH, et al. The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020;60(3):375–90.

40. Tabrizi R, Tamtaji OR, Lankarani KB, Mirhosseini N, Akbari M, Dadgostar E, et al. The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Lipids Health Dis. 2015;14:97.

41. Tabrizi R, Tamtaji OR, Lankarani KB, Mirhosseini N, Akbari M, Dadgostar E, et al. The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome receiving standard treatment. Clin Risk Manag. 2016;12:281.

42. Voigt K, Titt M, Pasca B, Buceta C, Uhvarson D, Endres L, et al. Long-term resveratrol supplementation as a secondary prophylaxis for stroke. Oxid Med Cell Longev. 2018;2018:447320.

43. Mazzu A, Scialov V, Rigatelli G, Torin G, Montanaro F, Lentini S. The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Food Funct. 2018;9:3845–52.

44. van der Made SM, Plat J, Mensink RP. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS One. 2015;10(3):e0118393. https://doi.org/10.1371/journal.pone.0118393.

45. de Ligt M, Bruls YMH, Hansen J, Habels MF, Havekes L, Basmaci EBM, et al. Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes. Mol Metab. 2018;12:39–47.

46. Simental-Mendia LE, Guerrero-Romero F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: a randomized double-blind, placebo-controlled trial. Nutrition. 2019;57:8–10. https://doi.org/10.1016/j.nut.2018.06.015.

47. Fodor K, Till DM, Pasca B, Buceta C, Uhvarson D, Endres L, et al. Long-term resveratrol supplementation as a secondary prophylaxis for stroke. Oxid Med Cell Longev. 2018;2018:447320.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.